Company intelligence / Profile preview

Borealis Biotechnology

Vancouver, British Columbia, Canadadnb.com ↗

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Borealis Biosciences emerged from stealth in August 2024 with $150 million Series A funding. It leverages a proprietary xRNA platform developed by Novartis, aiming to develop next-generation RNA medicines for chronic kidney diseases. The team includes former Chinook Therapeutics researchers and global experts in kidney research and RNA delivery. No clinical results have been reported yet; programs are at the discovery/preclinical stage.

Therapeutic areas: Nephrology
Modalities: RNA therapy (specifically xRNA-based medicines)
Industry: Biotech

Partnerships

Versant Ventures (founding investor)Novartis AG (strategic partner: technology provider, major investor, future option rights on development-ready assets)

Beyond the preview

Go deeper on Borealis Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Borealis Biotechnology.

Explore the full profile